Molecular Health Raises 25 Million Euros in Private Financing

HEIDELBERG, Germany and BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Molecular Health, a leader in cloud-based healthcare decision support technology to enable evidence-based treatment decisions and improved outcomes, today announced that it has raised €25 million in private financing to expand commercial adoption of its healthcare decision engine. The round was led by current investor dievini, an investor in global life and health sciences companies. With the completion of this round of financing, Molecular Health has raised a total of approximately €100 million.

"Big data is largely driving decision-making for today's physicians, diagnostic labs, and pharmaceutical companies. However, the sheer volume of data that exists today and its continuous, rapid expansion makes it increasingly complicated to digest and apply in a practical way," said Lutz Voelker, Chief Executive Officer of Molecular Health. "Our platform integrates these data into the most comprehensive biomedical data warehouse in the world and quickly interprets information to generate accurate and actionable insights that drive important healthcare decisions, leading to both personalized treatment and more efficient therapy development. We greatly appreciate the continued support of dievini and look forward to expanding the company's commercial infrastructure and driving adoption of our solutions."

"Medicine is in one of its biggest changes ever, as molecular data and information are becoming the new currency in healthcare," said Friedrich von Bohlen, Chairman of the Board of Directors and Managing Director of dievini. "We recognized long ago that Molecular Health was one of the most forward-thinking organizations in healthcare, with the unique potential to improve outcomes and health through the power of integrative computing and IT-based interpretation. We are excited to expand our support of Molecular Health, who is at the forefront of modern medicine, helping people in healthcare organizations improve understanding, interpretation and decision making."

About Molecular Health

Molecular Health is a leading biomedical company that is transforming molecular data and medical knowledge into actionable clinical information for more efficient and safe targeted therapies for each individual patient. Molecular Health generates individualized analysis and clinical interpretation for evidence-based targeted therapy identification utilizing published medical knowledge in a clinical context. In Europe, Molecular Health has the first registered medical device of its kind for personalized cancer medicine. Molecular Health Inc., headquartered in Boston, MA, with a laboratory and support center in Greater Houston, TX, is a wholly owned subsidiary of Molecular Health GmbH, headquartered in Heidelberg, Germany. To learn more, please visit: